Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- RaQualia, Nagoya University Sign Industry-Academia Partnership Deal
February 20, 2014
- Future Relationship of Nichi-Iko and Sanofi in Question with Discontinuation of Biosimilar Codevelopment; Will They Continue to Work Together for Second AG?
February 20, 2014
- Astellas, AVEO Jettison Joint Development of Anticancer Agent Tivozanib
February 19, 2014
- Fujifilm Accepts Subscription Rights to J-TEC’s New Shares at 540 Million Yen, Commissioning Regenerative Medicine Products
February 19, 2014
- Eiken Chemical Taps Sales Division Head as New President
February 18, 2014
- US Biotech Acucela Makes Debut on TSE’s Mothers Market
February 18, 2014
- MTPC, JB to End Copromotion of Blood Plasma Products
February 18, 2014
- Nissan Chemical Sues Three More Generic Makers over Livalo Patent Infringement
February 18, 2014
- Daiichi Sankyo, UMN Pharma Sign Collaborative Research Deal for Norovirus Vaccine
February 18, 2014
- Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
- Kissei, Alteogen Agree on Business Collaboration for Biosimilar Development
February 17, 2014
- LEO Pharma’s New Japan Head Takes Office
February 17, 2014
- Once-Monthly Injectable Abilify Maintena Approved in Canada: Otsuka, Lundbeck
February 17, 2014
- New Suspicion Hints Close Link between Novartis, SIGN Initiator Group
February 17, 2014
- Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
- Qol to Introduce Bidding System for Drug Purchasing Aimed at Avoiding Reduction in Basic Dispensing Fees Received
February 14, 2014
- Ex-Bellsystem24 Exec Deguchi to Spearhead AbbVie Japan
February 13, 2014
- Kyowa Kirin Temporarily Drops Untreated ATL Indication for Poteligeo
February 13, 2014
- Kaken Licenses Container Technology for Efinaconazole to Valeant
February 13, 2014
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…